Merkel cell carcinoma clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For Merkel cell carcinoma patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of Merkel cell carcinoma clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 11 of 11 trials

Start new search

A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and in Combination with NKTR-214 plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03435640

View Trial

A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)

LODESTAR: A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

Investigator:

Gabriela Chiorean

Study ID:

NCT04171700

View Trial

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03767348

View Trial

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

A Phase 1b/2 Study of AST-008 Combined with Pembrolizumab in Patients with Advanced Solid Tumors

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03684785

View Trial

A Study to Evaluate the Safety, Tolerability of DN1508052-01 to Advanced Solid Tumors

A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of DN1508052-01 as a Single Agent when Administered Subcutaneously to Adult Patients with Advanced Solid Tumors

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03934359

View Trial

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

ATTAC-MCC: Phase I/II study of Autologous CD8+ and CD4+ Transgenic T cells expressing high affinity MCPyV-specific TCRs combined with Avelumab and Class I MHC -upregulation in patients with metastatic MCC refractory to PD-1 axis blockade

Investigator:

Joshua Veatch, MD, PhD

Study ID:

NCT03747484

View Trial

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

INCMGA 0012-201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03599713

View Trial

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation

Investigator:

Andrew Coveler, MD

Study ID:

NCT03600883

View Trial

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03289962

View Trial

Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors

Investigator:

Christina S. Baik, MD, MPH

Study ID:

NCT03037385

View Trial

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03271372

View Trial